Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
Journal
Journal of the Formosan Medical Association
Date Issued
2021
Author(s)
Yang T.-S.
Hsu T.-C.
Tzu-Liang Chen W.
Chen H.-H.
Teng H.-W.
Lin B.-W.
Kuan F.-C.
Chiang F.-F.
Duann C.-W.
Li Y.-S.
Lin M.-T.
Fiala-Buskies S.
Ducreux M.
Wang J.-Y.
Abstract
Background/Purpose: This analysis reports safety and effectiveness data from the Taiwanese cohort of the CORRELATE study. Methods: CORRELATE was a prospective, observational study to assess the safety and effectiveness of regorafenib for the treatment of metastatic colorectal cancer (CRC) in real-world clinical practice that was conducted in 13 different countries in Asia, Europe and Latin America. The primary endpoint of the study was incidence of all treatment-emergent AEs (TEAEs), and secondary endpoints included overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Results: The global study population (N = 1037) included 128 Taiwanese patients with a median age of 64 years, median weight of 62.02 kg and 66.41% were male. Reduced initiating doses of regorafenib and dose interruptions were common in Taiwanese patients (71.87% and 50.00%, respectively). The safety profile of regorafenib was consistent with that seen in Asian patients in the clinical development trials, including the CORRECT and CONCUR studies, with hand–foot–skin reactions (HFSR) of any grade occurring in 33.59% of patients. Median OS was 11.64 months in the Taiwanese patients (95% confidence interval [CI], 8.36–13.82) and median PFS was 2.17 months (95% CI, 1.97–2.89). Conclusion: The safety and effectiveness of regorafenib in this real-world study was generally consistent with the known efficacy and safety profile in Asian patients in clinical trials. Trial registration: NCT02042144.
SDGs
Publisher
Elsevier B.V.
Type
journal article